Background: Mechanisms underlying osteoporosis in chronic cholestasis are complex and poorly understood. In this setting, osteoporosis mainly results from low bone formation, related to the effects of retained substances of cholestasis, such as bilirubin and bile acids. Thus, in "in vitro" studies, unconjugated bilirubin and serum from jaundiced patients decrease osteoblast viability, differentiation and mineralization. However, the influence of cholestasis on osteocytes, the most ubiquitous cells of the skeleton, is unknown. Objectives: The aim of this study was to analyze the direct effects of increased molecules of cholestasis, such as bilirubin (Bil) and lithocholic acid (LCA), and the potential protective effect of ursodeoxycholic acid (UDCA) on the osteocytes. Methods: MLO-Y4 and MLO-A5 osteocyte cell lines treated at different times and concentrations with Bil, LCA and UDCA were used to determine: 1) Viability: WST colorimetric method; 2) Differentiation: quantification of alkaline phosphatase (AP) activity; 3) Mineralization: Alizarin red staining quantification; and 4) Apoptosis: quantification of DNA fragmentation and caspase-3 activity. Results: LCA (100μM) and Bil (50μM) significantly decreased viability in MLO-Y4 from 72 hours (10%) and 48 hours (11%), respectively (p≤0.01), and Bil decreased viability (49%) in MLO-A5 from 96 hours (p<0.01). Bil decreased AP activity by 47% after 96 hours, under conditions of differentiation in MLO-Y4 (p≤0.01). There were no effects on AP activity in MLO-A5. After 14 days, Bil was associated with a significant mineralization decrease, as high as 87%, in MLO-A5 (p≤0.02). Moreover, Bil and LCA increased apoptosis in MLO-Y4, determined by DNA fragmentation (242% and 119%, respectively) and caspase-3 activity (190% and 251%, respectively) (p≤0.01) after 24 hours. In contrast, UDCA (100 μM) increased viability after 72 hours (11%) and decreased the deleterious effects of LCA or BiI (p≤0.02). UDCA increased AP activity in MLO-Y4 after 72 hours under growth conditions (p=0.018), and after 24 hours under differentiation conditions (p≤0.01). Conclusions: Bilirubin and lithocholic acid have damaging effects on osteocytic cells decreasing viability, differentiation and mineralization, and increasing apoptosis, effects that are neutralized by the UDCA. These results indicate that substances retained in cholestasis impair osteocytic functions, and therefore may be involved in the pathogenesis of osteoporosis in cholestatic diseases.
Objectives: To compair two questionaires:a specific one-Osteoporosis Quality of Life Questionnaire (OQLQ) and a general one-Short Form-36 (SF-36),in women with decreased mineral bone density (BMD) and vertebral fractures,and to estimate which one is more useful for everyday work. Methods: Cross-section study included 50 menopausal women with osteoporosis (OP), who were assessed with the general questionaire,and all known risk factors for osteoporosis were confirmed. Osteodensitometry scan (DXA) was performed on lumbar spine,and based both on T index value and BMD the subjects were divided in two groups:first grour (women with OP, n=25),second group (women with fractures of spinal vertebra due to OP,regardless of BMD, n=25, and with at least 4 months since the last fracture).The quality of life was assessed by two questionaires:a specific one OQLQ-consists of 30 questions divided into 5 areas,which are evaluated from 1 to 7 (the lower the score the more sever function damage and worse quality of life) and the general questionnaire SF-36-containing 36 questions divided into 8 areas (scores from 0 to 100, where the lower value is also a poorer quality of life).Questionnaires were converted to get two summarized scales,so as to obtain the total score for:physical (PCS) and mental functions (MCS).The two questionnaires were compared using appropriate statistical methods in SPSS. Results: There was no significant differencev between groups regarding: mean age (first=63.3±6.0, second=64.9±7.8),mean age at the start of the menopause (first=46.8±5.3, second=48.2±4.2 years), mean duration of menopause (first=16.4±6.9, second=17.1±6.9 year),but there was statistically significant difference between the number of risk factors for OP (first=1.8±1.2, second=2.8±0.9, p<0.01).Statistically significant between group difference (p<0.01) in mean BMD and T score (first-BMD 0.807±0.057gr/cm 2 ,T scor -3.12±0.49SD, second-BMD 0.931±0.172 gr/cm 2 ,T score -2.09±1.45SD).The following DXA values were measured in the second group:8 patients-normal,6-osteopenia,11-osteoporosis,with average number of fractures 2.6±0. During the mean 12-month follow-up period, there were no unexpected adverse event [AE] or severe adverse event, no graft failure and no deaths. No patient experienced fracture. Only one patient presented an infectious AE with recurrent cutaneous abscess. Renal function remained stable with no difference in serum creatinine between baseline and 12 months for the majority of the kidney transplant recipients. However, 9 recipients experienced a decrease in renal function with a mean increased in serum creatinine of 32.5micromol/L between baseline and 12 months. Serum calcium was stable, no hypocalcaemia was observed. Among patients with normal baseline PTH, two presented hyperparathyroidism during the follow-up period. Among the 11 patients with baseline hyperparathyroidism, 7 had an increased PTH level between baseline and 12 months. None were initiated on cinacalcet. Conclusions: Our results suggest that denosumab is safe in kidney transplant recipients. We did not observe an increase in the infection rates, nor hypocalcemia. However, several patients experienced a decrease in their renal function or an increased hyperparathyroidism. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.6899 
